Literature DB >> 17517444

Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.

Ala Yaromina1, Marie Krause, Howard Thames, Andrea Rosner, Mechthild Krause, Franziska Hessel, Reidar Grenman, Daniel Zips, Michael Baumann.   

Abstract

OBJECTIVE: The response of tumours to fractionated radiotherapy is determined by many factors including repopulation, reoxygenation, the number of clonogenic cells, and their intrinsic radiosensitivity. However, after single radiation doses given under conditions of clamp hypoxia, the dose to control a tumour locally is dependent only on the number of clonogenic cells and their cellular radiosensitivity. Therefore, these parameters were investigated using local control after single doses given under hypoxia, to predict the outcome of fractionated irradiation.
MATERIALS AND METHODS: Ten hSCC cell lines (FaDu, UT-SCC-15, UT-SCC-14, XF354, UT-SCC-5, UT-SCC-45, SAS, CAL-33, UT-SCC-8, and HSC-4) were transplanted subcutaneously into the right hind-leg of NMRI nude mice. At 7mm in diameter, tumours were irradiated either with graded single doses under clamp blood flow conditions (n=873) or with 30 graded fractions within 6 weeks (n=905) under ambient conditions. Local tumour control was determined 120 days after irradiation. Radiation response was quantified in terms of TCD(50), i.e. the dose required to control 50% of tumours locally.
RESULTS: Ten tumour lines investigated showed a pronounced heterogeneity in both TCD(50(30fx/6w)) after fractionated irradiation and TCD(50(SDclamp)) after single dose irradiation. TCD(50(30fx/6w)) varied between 45Gy for UT-SCC-45 and 127Gy for SAS; TCD(50(SDclamp)) varied between 42Gy for UT-SCC-14 and 66Gy for CAL-33. Two tumours were excluded from further analysis due to immunogenicity or non-defined TCD(50). Linear regression analysis revealed a significant positive correlation between TCD(50(SDclamp)) and TCD(50(30fx/6w)) (R(2)=0.82, p=0.002).
CONCLUSIONS: Significant association between TCD(50(SDclamp)) and TCD(50(30fx/6w)) suggests that the pre-treatment number of clonogenic tumour cells and their cellular radiosensitivity have a major impact on local control after fractionated radiotherapy.

Entities:  

Mesh:

Year:  2007        PMID: 17517444     DOI: 10.1016/j.radonc.2007.04.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  51 in total

1.  PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.

Authors:  Iris Eke; Ulrike Koch; Stephanie Hehlgans; Veit Sandfort; Fabio Stanchi; Daniel Zips; Michael Baumann; Anna Shevchenko; Christian Pilarsky; Michael Haase; Gustavo B Baretton; Véronique Calleja; Banafshé Larijani; Reinhard Fässler; Nils Cordes
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Nanoparticles: a promising modality in the treatment of sarcomas.

Authors:  Michiro Susa; Lara Milane; Mansoor M Amiji; Francis J Hornicek; Zhenfeng Duan
Journal:  Pharm Res       Date:  2010-05-27       Impact factor: 4.200

3.  [Translational uroradio-oncology].

Authors:  S E Combs; J Debus
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

4.  Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Authors:  Qi Liu; Meng Wang; Ashley M Kern; Saman Khaled; Jing Han; Beow Y Yeap; Theodore S Hong; Jeff Settleman; Cyril H Benes; Kathryn D Held; Jason A Efstathiou; Henning Willers
Journal:  Mol Cancer Res       Date:  2015-02-09       Impact factor: 5.852

5.  Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a.

Authors:  Xigang Hu; Huijuan Jiang; Xiaojun Jiang
Journal:  Cancer Biol Ther       Date:  2017-04-12       Impact factor: 4.742

Review 6.  [Prediction of the reaction of normal tissue and tumor cells to radiotherapy].

Authors:  E Dikomey; J Dahm-Daphi; L Distel
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

Review 7.  Individualization of cancer treatment from radiotherapy perspective.

Authors:  Ala Yaromina; Mechthild Krause; Michael Baumann
Journal:  Mol Oncol       Date:  2012-02-09       Impact factor: 6.603

8.  Prognostic value of HIF-1α expression during fractionated irradiation.

Authors:  L Helbig; A Yaromina; S N Sriramareddy; S Böke; L Koi; H D Thames; M Baumann; D Zips
Journal:  Strahlenther Onkol       Date:  2012-09-29       Impact factor: 3.621

Review 9.  The changing paradigm of tumour response to irradiation.

Authors:  Richard P Hill
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

Review 10.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.